--> MRK no premarket for now
Merck beats by $0.04, reports revs in-line; guides FY15 EPS above consensus, revs in-line
- Reports Q3 (Sep) earnings of $0.96 per share, $0.04 better than the Capital IQ Consensus of $0.92; revenues fell 4.3% year/year to $10.1 bln vs the $10.08 bln Capital IQ Consensus.
- Co issues guidance for FY15, sees EPS of $3.55-3.60 vs. $3.50 Capital IQ Consensus Estimate; sees FY15 revs of $39.2-39.8 bln vs. $39.64 bln Capital IQ Consensus Estimate.
- Q3 KEYTRUDA sales were approximately $160 million